The contribution of the monocyte-macrophage lineage to immunotherapy outcomes
Blood · 06.03.2025 · 145 (10) · 1010-1021
DOI: 10.1182/blood.2024025680 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood, erschienen am 06.03.2025. Verfasst von Rachael C Adams und 2 weiteren Autor:innen. Beteiligte Einrichtung: Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Hauptthemen laut MEDLINE: Macrophages, Monocytes, Immunotherapy, Graft vs Host Disease. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Macrophages execute core functions in maintaining tissue homeostasis, in which their extensive plasticity permits a spectrum of functions from tissue remodeling to immune defense. However, perturbations to tissue-resident macrophages during disease, and the subsequent emergence of monocyte-derived macrophages, can hinder tissue recovery and promote further damage through inflammatory and fibrotic programs. Gaining a fundamental understanding of the critical pathways defining pathogenic macrophage populations enables the development of targeted therapeutic approaches to improve disease outcomes. In the setting of chronic graft-versus-host disease (cGVHD), which remains the major complication of allogeneic hematopoietic stem cell transplantation, colony-stimulating factor 1 (CSF1)–dependent donor-derived macrophages have been identified as key pathogenic mediators of fibrotic skin and lung disease. Antibody blockade of the CSF1 receptor (CSF1R) to induce macrophage depletion showed remarkable capacity to prevent fibrosis in preclinical models and has subsequently demonstrated impressive efficacy for improving cGVHD in ongoing clinical trials. Similarly, macrophage depletion approaches are currently under investigation for their potential to augment responses to immune checkpoint inhibition. Moreover, both monocyte and tissue-resident macrophage populations have recently been implicated as mediators of the numerous toxicities associated with chimeric antigen receptor T-cell therapy, further highlighting potential avenues of macrophage-based interventions to improve clinical outcomes. Herein, we examine the current literature on basic macrophage biology and contextualize this in the setting of cellular and immunotherapy. Additionally, we highlight mechanisms by which macrophages can be targeted, largely by interfering with the CSF1/CSF1R signaling axis, for therapeutic benefit in the context of both cellular and immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
- Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.
ORCID-Profile: Rachael C Adams
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NIAID NIH HHS
Zitieren
APA
Adams, R. C., MacDonald, K. P. A., & Hill, G. R. (2025). The contribution of the monocyte-macrophage lineage to immunotherapy outcomes. Blood, 145(10), 1010-1021. https://doi.org/10.1182/blood.2024025680
Vancouver
Adams RC, MacDonald KPA, Hill GR. The contribution of the monocyte-macrophage lineage to immunotherapy outcomes. Blood. 2025;145(10):1010-1021. doi:10.1182/blood.2024025680
BibTeX
@article{Adams2025,
author = {Adams, Rachael C and MacDonald, Kelli P A and Hill, Geoffrey R},
title = {The contribution of the monocyte-macrophage lineage to immunotherapy outcomes},
journal = {Blood},
year = {2025},
volume = {145},
number = {10},
pages = {1010--1021},
doi = {10.1182/blood.2024025680}
}
EUVIMED